Cargando…
The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure
AIMS: Acute heart failure (HF) is associated with muscle mass loss, potentially leading to overestimation of kidney function using serum creatinine‐based estimated glomerular filtration rate (eGFR(sCr)). Cystatin C‐based eGFR (eGFR(CysC)) is less muscle mass dependent. Changes in the difference betw...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715858/ https://www.ncbi.nlm.nih.gov/pubmed/35762103 http://dx.doi.org/10.1002/ehf2.13975 |
_version_ | 1784842551067410432 |
---|---|
author | Pinsino, Alberto Fabbri, Matteo Braghieri, Lorenzo Bohn, Bruno Gaudig, Antonia J. Kim, Andrea Takeda, Koji Naka, Yoshifumi Sayer, Gabriel T. Uriel, Nir Demmer, Ryan T. Faillace, Robert T. Husain, Syed A. Mohan, Sumit Colombo, Paolo C. Yuzefpolskaya, Melana |
author_facet | Pinsino, Alberto Fabbri, Matteo Braghieri, Lorenzo Bohn, Bruno Gaudig, Antonia J. Kim, Andrea Takeda, Koji Naka, Yoshifumi Sayer, Gabriel T. Uriel, Nir Demmer, Ryan T. Faillace, Robert T. Husain, Syed A. Mohan, Sumit Colombo, Paolo C. Yuzefpolskaya, Melana |
author_sort | Pinsino, Alberto |
collection | PubMed |
description | AIMS: Acute heart failure (HF) is associated with muscle mass loss, potentially leading to overestimation of kidney function using serum creatinine‐based estimated glomerular filtration rate (eGFR(sCr)). Cystatin C‐based eGFR (eGFR(CysC)) is less muscle mass dependent. Changes in the difference between eGFR(CysC) and eGFR(sCr) may reflect muscle mass loss. We investigated the difference between eGFR(CysC) and eGFR(sCr) and its association with clinical outcomes in acute HF patients. METHODS AND RESULTS: A post hoc analysis was performed in 841 patients enrolled in three trials: Diuretic Optimization Strategy Evaluation (DOSE), Renal Optimization Strategies Evaluation (ROSE), and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS‐HF). Intra‐individual differences between eGFRs (eGFR(diff)) were calculated as eGFR(CysC)–eGFR(sCr) at serial time points during HF admission. We investigated associations of (i) change in eGFR(diff) between baseline and day 3 or 4 with readmission‐free survival up to day 60; (ii) index hospitalization length of stay (LOS) and readmission with eGFR(diff) at day 60. eGFR(CysC) reclassified 40% of samples to more advanced kidney dysfunction. Median eGFR(diff) was −4 [−11 to 1.5] mL/min/1.73 m(2) at baseline, became more negative during admission and remained significantly different at day 60. The change in eGFR(diff) between baseline and day 3 or 4 was associated with readmission‐free survival (adjusted hazard ratio per standard deviation decrease in eGFR(diff): 1.14, P = 0.035). Longer index hospitalization LOS and readmission were associated with more negative eGFR(diff) at day 60 (both P ≤ 0.026 in adjusted models). CONCLUSIONS: In acute HF, a marked difference between eGFR(CysC) and eGFR(sCr) is present at baseline, becomes more pronounced during hospitalization, and is sustained at 60 day follow‐up. The change in eGFR(diff) during HF admission and eGFR(diff) at day 60 are associated with clinical outcomes. |
format | Online Article Text |
id | pubmed-9715858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97158582022-12-05 The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure Pinsino, Alberto Fabbri, Matteo Braghieri, Lorenzo Bohn, Bruno Gaudig, Antonia J. Kim, Andrea Takeda, Koji Naka, Yoshifumi Sayer, Gabriel T. Uriel, Nir Demmer, Ryan T. Faillace, Robert T. Husain, Syed A. Mohan, Sumit Colombo, Paolo C. Yuzefpolskaya, Melana ESC Heart Fail Original Articles AIMS: Acute heart failure (HF) is associated with muscle mass loss, potentially leading to overestimation of kidney function using serum creatinine‐based estimated glomerular filtration rate (eGFR(sCr)). Cystatin C‐based eGFR (eGFR(CysC)) is less muscle mass dependent. Changes in the difference between eGFR(CysC) and eGFR(sCr) may reflect muscle mass loss. We investigated the difference between eGFR(CysC) and eGFR(sCr) and its association with clinical outcomes in acute HF patients. METHODS AND RESULTS: A post hoc analysis was performed in 841 patients enrolled in three trials: Diuretic Optimization Strategy Evaluation (DOSE), Renal Optimization Strategies Evaluation (ROSE), and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS‐HF). Intra‐individual differences between eGFRs (eGFR(diff)) were calculated as eGFR(CysC)–eGFR(sCr) at serial time points during HF admission. We investigated associations of (i) change in eGFR(diff) between baseline and day 3 or 4 with readmission‐free survival up to day 60; (ii) index hospitalization length of stay (LOS) and readmission with eGFR(diff) at day 60. eGFR(CysC) reclassified 40% of samples to more advanced kidney dysfunction. Median eGFR(diff) was −4 [−11 to 1.5] mL/min/1.73 m(2) at baseline, became more negative during admission and remained significantly different at day 60. The change in eGFR(diff) between baseline and day 3 or 4 was associated with readmission‐free survival (adjusted hazard ratio per standard deviation decrease in eGFR(diff): 1.14, P = 0.035). Longer index hospitalization LOS and readmission were associated with more negative eGFR(diff) at day 60 (both P ≤ 0.026 in adjusted models). CONCLUSIONS: In acute HF, a marked difference between eGFR(CysC) and eGFR(sCr) is present at baseline, becomes more pronounced during hospitalization, and is sustained at 60 day follow‐up. The change in eGFR(diff) during HF admission and eGFR(diff) at day 60 are associated with clinical outcomes. John Wiley and Sons Inc. 2022-06-27 /pmc/articles/PMC9715858/ /pubmed/35762103 http://dx.doi.org/10.1002/ehf2.13975 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Pinsino, Alberto Fabbri, Matteo Braghieri, Lorenzo Bohn, Bruno Gaudig, Antonia J. Kim, Andrea Takeda, Koji Naka, Yoshifumi Sayer, Gabriel T. Uriel, Nir Demmer, Ryan T. Faillace, Robert T. Husain, Syed A. Mohan, Sumit Colombo, Paolo C. Yuzefpolskaya, Melana The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure |
title | The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure |
title_full | The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure |
title_fullStr | The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure |
title_full_unstemmed | The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure |
title_short | The difference between cystatin C‐ and creatinine‐based assessment of kidney function in acute heart failure |
title_sort | difference between cystatin c‐ and creatinine‐based assessment of kidney function in acute heart failure |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715858/ https://www.ncbi.nlm.nih.gov/pubmed/35762103 http://dx.doi.org/10.1002/ehf2.13975 |
work_keys_str_mv | AT pinsinoalberto thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT fabbrimatteo thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT braghierilorenzo thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT bohnbruno thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT gaudigantoniaj thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT kimandrea thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT takedakoji thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT nakayoshifumi thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT sayergabrielt thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT urielnir thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT demmerryant thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT faillacerobertt thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT husainsyeda thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT mohansumit thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT colombopaoloc thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT yuzefpolskayamelana thedifferencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT pinsinoalberto differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT fabbrimatteo differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT braghierilorenzo differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT bohnbruno differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT gaudigantoniaj differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT kimandrea differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT takedakoji differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT nakayoshifumi differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT sayergabrielt differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT urielnir differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT demmerryant differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT faillacerobertt differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT husainsyeda differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT mohansumit differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT colombopaoloc differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure AT yuzefpolskayamelana differencebetweencystatincandcreatininebasedassessmentofkidneyfunctioninacuteheartfailure |